Gan & Lee Pharmaceuticals: Insulin Aspart Injection receives marketing authorization from the European Commission

Golden Ten Data, May 6 – Gan & Lee Pharmaceuticals announced that the company and its wholly owned European subsidiary, Gan & Lee Europe, recently received notification from the European Commission that the company’s product, insulin aspart injection, has been granted marketing authorization in the European Union, Iceland, Liechtenstein, and Norway, for the treatment of diabetes in adults, adolescents, and children aged one year and older.